Pharmaceuticals

HGF has one of the largest and most experienced pharmaceutical patent attorney/lawyer teams in Europe.  Many of our attorneys and solicitors have joined from large pharmaceutical companies and bring extensive in-house experience of building, managing enforcing and defending global patent portfolios protecting some of the highest profile medicines in Europe.

Our multidisciplinary team supports clients through all stages of the development and lifespan of a pharmaceutical product. We specialise in providing IP strategy advice, invention capture, drafting and filing patent applications, patent prosecution, infringement analysis, EPO oppositions/appeals, commercialisation across the life cycle and multi-jurisdictional patent litigation. We also have specialist experience of supplementary protection certificates (SPCs), regulatory data exclusivity and IP due diligence. A large part of our pharmaceutical practice involves contentious proceedings in the courts and at the EPO. A number of our experienced patent attorneys specialise in opposition and appeal proceedings before the European Patent Office and are regularly involved with complex and high-value multi-party oppositions. Our team of solicitors, working together with our patent attorneys, are also regularly involved in high-profile pharmaceutical patent disputes i nthe national Courts and across Europe.

In terms of technical expertise, our multidisciplinary team specialises in IP relating to drug compounds, particular forms of drug compounds (salt, solvates and polymorphs), formulations (including advanced drug delivery systems), processes for making drug compounds, methods of treatment and therapeutic uses (including drug repositioning), dosage regimens, combination therapies, drug conjugates (such as antibody drug conjugates and PROTACs) and neutraceuticals.

 

Medicine testing
Technician holding medicine bottles

Our pharmaceuticals specialists

We’ve built our business by recruiting and developing specialists, not generalists. When it comes to protecting your ideas and business, you want to know you’re working with the best – people who truly understand your sector and the potential of your IP.

HGF’s team has pharmaceuticals professionals from an array of academic and business backgrounds. Our team-based approach ensures our clients benefit from the very best strategic advice from people who understand not only the legal environment but also the practical side of your business.

Let's talk

If you would like to discuss how HGF could help you, contact one of our pharmaceuticals specialists.

Latest news

Polymorphs: Clearing the Inventive Step Hurdle at the European Patent Office (EPO)

Polymorphic forms of active pharmaceutical ingredients (APIs) can represent commercially valuable compound subject matter and can be critical to providing necessary drug product characteristics and performance. However, patenting polymorphs is …

Read article

IQPC Global US Exchange

HGF are proud ‘Silver Plus’ sponsors of the IQPC Global US Exchange, at the Austin Marriot South, Texas. The IQPC Global US Exchange will be held at the Austin Marriot …

Read article

Update on the Precision Breeding Act 2023: details emerge of the new simplified regulatory pathway for gene edited plant and animal derived food and feed products

The Genetic Technology (Precision Breeding) Act 2023 could come into force as early as spring 2025. It empowers the Food Standards Agency (FSA) to create a new simplified regulatory pathway …

Read article

Court of Appeal Decision Upholds Invalidity of Patent Due to Amendment Identifying Embodiment as Outside the Scope of the Claims

In a case that highlights the challenges arising due to post-grant amendments, and in particular interpretation of the claims in view of the description, the Court of Appeal in Ensygnia …

Read article

UPC Court of Appeal clarifies approach for interpreting claims with “obvious” errors

Alexion Pharmaceuticals, Inc. v Samsung Bioepis NL B.V. [UPC_CoA_402/2024] –Court of Appeal of the UPC (Grabinski, Blok, Gougé, Enderlin, Hedberg) – 20 December 2024 Alexion Pharmaceuticals, Inc. v Amgen Technology …

Read article

IP Ingredients: Winter Case Law Review 2024

As the nights draw in and the frenzy to finish everything off before the holiday season reaches its peak, it’s time to take a break, grab your favourite hot beverage …

Read article